The National Institutes of Health today unveiled a collaborative program that will match researchers with a selection of pharmaceutical industry compounds to help scientists explore new treatments for patients. NIH’s new National Center for Advancing Translational Sciences (NCATS) has partnered initially with Pfizer, AstraZeneca, and Eli Lilly and Company which have agreed to make dozens of their compounds available for this initiative’s pilot phase.

Related posts:

  1. Therapeutics for Rare and Neglected Diseases Program announces next round of drug development projects Researchers will begin drug development projects for rare and neglected diseases that include potential treatments for a musculoskeletal disorder, a cognitive dysfunction disorder, a virus that affects the central nervous system of newborns, a parasitic worm infection, a form of muscular dystrophy and a rare lung disease....
  2. High-quality preschool program produces long-term economic payoff An early education program for children from low-income families is estimated to generate $4 to $11 of economic benefits over a child*’s lifetime for every dollar spent initially on the program, according to a cost-benefit analysis funded by the National Institutes of Health....
  3. Medicare Card, National Institutes of Health launches summer institute on mHealth The National Institutes of Health today announced the creation of the first NIH Health, or mobile health, Summer Institute. Scheduled for the summer of 2011, this week-long workshop will bring together leaders in mobile health technologies, behavioral science researchers, federal health officials and members of the medical community to provide early career investigators with an […]...
  4. NIH Director Announces Appointment of James Anderson as Director of the NIH Division of Program Coordination, Planning, and Strategic Initiatives National Institutes of Health Director Francis S. Collins, M.D., Ph.D., announced today the appointment of James M. Anderson, M.D., Ph.D., as the Director of the NIH Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI). We anticipate his arrival in September 2010....
  5. Medicare, Novel Therapeutic Approach, Shows Promise Against Multiple Bacterial Pathogens A team of scientists from government, academia and private industry has developed a novel treatment that protects mice from infection with the bacterium that causes tularemia, a highly infectious disease of rodents, sometimes transmitted to people, and also known as rabbit fever. In additional experiments with human immune cells, the treatment also demonstrated protection against […]...
  6. Partners with industry to create new Living Lab for research into molecular structures that can affect disease A new type of lab has been created to utilize near-atomic resolution microscopy and other structural biology technologies to help accelerate important medical discoveries relating to global health challenges, such as cancer and HIV/AIDS. The Living Lab Structural Biology Center was formed through a cooperative research and development agreement between the National Institutes of Health […]...
  7. Fair Housing Initiatives Program (FHIP) Education and Outreach Initiative Fair Housing Initiatives Program (FHIP) Education and Outreach Initiative...
  8. National Center for Advancing Translational Sciences In a move to re-engineer the process of translating scientific discoveries into new drugs, diagnostics, and devices, the National Institutes of Health has established the National Center for Advancing Translational Sciences (NCATS)....
  9. NHGRI funds development of revolutionary DNA sequencing technologies Researchers today received more than $14 million in grants to develop DNA sequencing technologies that will rapidly sequence a person’s genome for $1000 or less. The National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, awarded the grants to enable the everyday use of DNA sequencing technologies by biomedical researchers and […]...
  10. Blueprint empowers drug development for nervous system disorders The National Institutes of Health has made awards to investigators across the United States for an ambitious set of projects seeking to develop new drugs for disorders of the nervous system....
  11. NIDA Avant-Garde-Medications Development Award winners announced Scientists proposing to develop vaccines against methamphetamine and nicotine have been selected to receive NIDA’s second Avant-Garde Awards for Innovative Medication Development Research. The two scientists, Dr. Thomas Kosten, of Baylor College of Medicine, Houston, and Dr. Peter Burkhard, of the University of Connecticut, Storrs, will each receive $500,000 per year for five years to […]...
  12. Science News, Experimental Medication Lifts Depression Symptoms in Bipolar Disorder Within an Hour People with treatment-resistant bipolar disorder experienced relief from symptoms of depression in as little as 40 minutes after an intravenous dose of the anesthetic medication ketamine in a preliminary study; while the patient group was small, this work adds to evidence that compounds in the class to which ketamine belongs have potential as rapid and […]...
  13. New technique identifies first events in tumor development A novel technique that enables scientists to measure and document tumor-inducing changes in DNA is providing new insight into the earliest events involved in the formation of leukemias, lymphomas and sarcomas, and could potentially lead to the discovery of ways to stop those events....
  14. Medicare Medical Care, Rapid Development of Drug-Resistant, 2009 H1N1 Influenza Reported in Two Cases Two people with compromised immune systems who became ill with 2009 H1N1 influenza developed drug-resistant strains of virus after less than two weeks on therapy, report doctors from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Doctors who treat prolonged influenza infection should be aware that even a short course of antiviral treatment may lead to drug-resistant virus, say the authors, and clinicians should consider this possibility as they develop initial treatment strategies for their patients who have impaired immune function....
  15. John Buse to chair federal diabetes education program John Buse, M.D., Ph.D., of the University of North Carolina at Chapel Hill School of Medicine, has been named the new chair of the National Diabetes Education Program (NDEP), a joint program of the National Institutes of Health and the Centers for Disease Control and Prevention, NDEP announced today....